Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Study sponsor: Evolus, Inc. · EOLS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-22Actual
Enrollment · participants154Actual
Source updated2024-09-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.